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Genetic Mechanisms of Neoplasia in MEN 2
Charles E. Jackson,* and Robert A. Norum*

Several possible mechanisms for the initiation and progression of tumors in mulliple endocrine
neoplasia type 2 (MEN 2) merit consideration. Localization ofMEN2A to the pericentromeric area of
chromosome 10 indicates the sile of the inilial mutagenic evenl bul does not explain the tissue
specificity observed. The consistency of tissue involvement yjithin families, despite the variabilily
bet-ween families, suggests lhal the tumors result from separale but contiguous tissue-specific genes
arranged in a particular linear order Linkage studies in MEN 2A and 2B families are compatible wiih
this contiguous gene theory. Dala suggest that Knudson s rwo-mutational-event theory is applicable in
MEN2, wdh cellular hyperplasia resultingfrom the inilial heritable mutation. The second event could
he a homozygous allelic mutation, hut the lack of consistent loss of heterozygosity of chromo.some 10
markers in tumors suggests other mechanisms. Observations in MEN 2 may he explained by the
heritable chromo.some 10 mulalicm causing hyperplasia, wilh the hyperplastic ceUs being converted lo
cancer cells by second mutations al any of many possible sdes. Tumor progression probably involves
subsequeni evenls al other loci. These hypotheses may have imporlani clinical implications. (Henry
Ford Ho.sp Med J 1989;37:116-9)

E

instein (I) has been quoted as saying, "On principle, it is
quite wrong to try founding a theory on observable magnitudes alone. In reality the opposite happens. It is the theory
which decides what we can observe." We present some hypotheses on the mechanisms resulting in the neoplasms ofthe multiple endocrine neoplasia type 2 (MEN 2) syndromes.

Effects of the Inherited Mutation
In 1973, Wolfe and others (2) reported the new pathologic entity of C-cell hyperplasia in young members of MEN 2 families.
At this time we suggested (3) that this C-cell hyperplasia represented the manifestation of the first or inherited mutational event
preceding medullary thyroid cancer (MTC) in Knudson's (4)
two-mutational-event theory for the initiation of neoplasia.
Much later we realized that if C-cell hyperplasia were the result
of the heritable mutational event, it should be present in every
hereditary MTC case but in none of the sporadic cases. C-cell
hyperplasia distal to the cancers has thus served as a differentiating pathologic feature between sporadic and hereditary
MTC (5,6).
In studying the ages of onset for sporadic and hereditary palpable MTCs, we found that these age-of-onset curves fit Knudson's two-mutational model for the initiation of cancer (5).
Using G6PD studies. Bay lin and his group (7,8) found MTC and
pheochromocytomas to be the result of final clonal mutations in
hereditarily susceptible cells in MEN 2 patients, which also fits
with Knudson's theory (4). The finding of adrenal medullary hyperplasia in MEN 2 patients by the Mayo Clinic (9) and the New
England Medical Center (10) groups fits into this theory as well.
Like C-cell hyperplasia (I I), adrenal medullary hyperplasia is a
visible manifestation ofthe heritable mutational event.
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Tissue-Specific Effects of the Initial Mutation
Our collaborative studies with Tashjian (3,5,6) have provided
the opportunity to observe the spectrum of manifestations in
many MEN 2A families and a few MEN 2B (mucosal neuroma)
families. We observed that the tissues involved are generally
consistent within families, even though a variety of tumor involvement is noted between families. We have suggested that
this consistency of tissue involvement within a family could be
clinically useful in predicting those organs likely to be affected
in an individual (12). In our largest MEN 2 family with 37 affected members, we have observed MTC and parathyroid tumors but no pheochromocytomas or adrenal medullary hyperplasia even in six affected members aged 51 to 67 or in three
patients at autopsy. In this family we can operate on the thyroid
or parathyroid glands without great concern for adrenal tumors.
However, in families with the full spectrum of involvement,
many members with calcitonin elevations had to have their
pheochromocytomas removed before neck surgery could be
performed.
Because the pattern of tumor involvement does breed true
within the 12 MEN 2A and four MEN 2B families .studied longest and most thoroughly, we have postulated that the different
components of MEN 2 are the result of separate mutations that
may be tightly linked or adjacent and which have tissue-specific
functions (13). tn 1986, Schmickel (14) coined the term contiguous gene syndrome, citing as examples the f^ader-Willi and
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Table 1
Thmor Involvement in MEN 2 Kindreds and Linkage
Resuhs with Chromosome 10 Markers from the
Literature (16-25)
Linkage to
Chromosome
10 Markers""
Parathyroid MTC Pheochromocytomas Neuromas Max Lod
Scores
MEN 2A

-F
-F

-F
-F
-F
-F

-F

+

+

23.76
2.5
3.27
3.88

-F
-F

Table 2
MEN2B Versus Chromosome 10 Markers
9
Marker
DlOZI
RBP3
D10SI5
(MCK2)
D10S5

0.05

O.l

0.2

0.3

Peak
Lods

e al
Peak

4.32 3.87
0.24 1.58

3.41
1.52

2.45
1.09

1.47
0.57

4.33
1.59

0
0.062

2.38
1.10

1.91
0.82

1.29
0.45

2.46
1.12

0.060
0.075

0.001

4.33
-1.35
-0.72
- 1.93

1.11
-0.32

2.45
1.09

4 - PARATHYROID

-F
MEN 2B

0

-F

4.33
•"Nakamura et al (22) repori evidence for tight linkage between MEN2A and chromosome 10 markers in 27 MEN 2A families from 14 countries and no evidence for genetic
heterogeneity. Yamamoto et al (25) found tight linkage to RBP3 infiveJapanese families.

( ) - THYROID C CELLS
- ADRENAL MEDULLA

DiGeorge syndromes, the aniridia-Wrims tumor association,
and various beta-delta thalassemias. The partem of overlap
involvement in these 16 families is consistent with a particular
linear order of the specific adjacent or contiguous genes—
parathyroid, thyroid C-cells, adrenal medulla, and mucosal
neuromas (13) (Fig I). Experience with the retinoblastoma
model suggests that the same genes involved in initiation and
progression of the various MEN 2 tumors will be implicated in
the events causing various sporadic endocrine tumors (15).
A prediction of this contiguous gene theory in MEN 2 is that
studies should show linkage to the same general chromosomal
area in the two-component (MTC, parathyroid) families as in
the three-component (MTC, parathyroid, pheochromocytoma)
families. The linkage studies of Simpson et al (16), which included our two-component S family and three-component W
family, provided evidence for linkage to the same chromosome
10 markers. No definite linkage evidence has yet been reported
to indicate differences in gene location in other two- or threecomponent MEN 2 families (Table I) (16-25).
Another prediction of this theory is that the genes for MEN
2A and MEN 2B should be linked to markers on chromosome
10. Most MEN 2B cases are the result of new mutations. With
much assistance, we have been able to study ten MEN 2B families in whom data and DNA are available for two or three generations (Table 2). These families have provided strong evidence
for linkage of the MEN 2B gene to the chromosome 10 centromere marker (DIOZl) (26) with a lod score of 4.33 at a zero
recombination level (24). The peak lod score forMEN2B versus
DI0S15 (MCK2) was 2.46 at 9 = 0.06, and the peak lod score
for MEN2B versus RBP3 was 1.59 at 9 = 0.062. The lack of
crossovers with DIOZl and the crossover with RBP3 in the one
family suggest that D lOZ I is either closer than RBP3 to MEN2B
or that DIOZl and RBP3 are on opposite sides of the MEN 2B
gene. Multipoint analysis in MEN2B versus various chromosome 10 markers provides curves similar to those observed
with MEN2A and the same markers (22) (Fig 2).
A possible suggestion from the contiguous gene theory is that
the tumors in MEN 2 are initiated by deletions of tumor-suppressor genes as in the retinoblastoma model. The action of
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Fig 1—Suggested linear order of MEN 2 genes (13).
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Fig 2—Comparison between multipoint curves for MEN2A (22)
andMEN2B. ForMEN2A the map distances are from the female
map (22):forMEN2B the map distances are an average of male
and female distances.

these genes seems to be specific to certain tissues. Howeven no
chromosome 10 deletion was visible in 23 MEN 2 families
whose chromosomes we have studied by high-resolution chromosome techniques (27). Additionally, no consistent loss of heterozygosity of chromosome 10 markers has been found in MEN
2 tumors (28-32) as has been found with chromosome 13 markers in retinoblastomas (15).
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DNA Markers in Tumors
Landsvater et al (29) found losses of chromosome 10 markers
in only one of 42 tumors studied. Nelkin and others (30.31) have
described losses of all informative chromosome 10 markers in
two of 16 MTCs studied, with no losses in the pheochromocytoma of one of these patients or in the pheochromocytoma of that patient's sister Loss of heterozygosity of
chromosome 1 markers was reported by Mathew et al (28) in
1987, and alterations in a small area of the short arm of chromosome I was recently reported by Samaan et al (33). C D .
Jaines (personal communication, 1989) from Cavenee's laboratory and Henry Ford Hospital has found toss of heterozygosity
of a chromosome 17 restriction fragment length polymorphism
(RFLP) in a pheochromocytoma of a patient whose MTC did not
show the same toss. He has atso found tosses of heterozygosity
of several RFLPs on chromosome 13 in one case of far advanced
thyroid cancer and losses of a chromosome 22 RFLP and two
chromosome 20 RFLPs in another far advanced case. Although
this lack of consistent loss of heterozygosity of chromosome 10
markers suggests that the second event is not a toss of a large
segment homologous to the chromosome bearing the inherited
defect, a small deletion or point mutation in the normal allele
has not been excluded. If the second event is a homologous allelic deletion, the losses of heterozygosity elsewhere are most
likely changes associated with tumor progression.

recessive events at other loci. In 1973 we emphasized that, if Ccell hyperplasia were the manifestation of the initial heritable
mutation, the agents causing the second event would need to be
ubiquitous because of the high penetrance of the MEN 2 gene
(3). Perhaps this level of penetrance could best be explained by
the inherited chromosome 10 mutation causing both hyperplasia
and an increased suscepribility to mutation and by the hyperplastic cells being converted to cancer cells by second mutations
at any of many possible sites.

Clinical Implications

What we have suggested are some hypotheses as to mechanisms of neoplasia in the MEN 2 syndromes. Evidence favors
the view that Knudson's two-mutational-event theory is applicable in the initiation of the various tumors in MEN 2. Knud.son's
theory has much supporting evidence; when it should cease to
be known as theory and become Knudson's law should be only a
matter of time. What are the possible clinical implicafions of
Knudson's theory in MEN 2? Since the first mutational events
are heritable mutations, the ages of onset and sizes ofthe various
tumors should be quite variable depending on the time of the
chance occurrence of the second mutational event. It is even
possible that in some individuals the second event would, by
chance, never occur in any of the hereditarily susceptible cells or
that the additionally mutated cells might not survive, suggesting
nonpenetrance in those gene carriers. Easton et al (40) have emphasized the variability in age of penetrance of the gene based on
Effects of Further Mutations
clinical findings. However, it seems unlikely that true nonNelkin et al (31) have suggested that oncogenesis in MEN 2
penetrance of the gene occurs very often, if at all, in an indimay not occur by the same recessive mechanism as outlined by
vidual subjected eariy in life to periodic stimulated calcitonin
Cavenee et al (15) for retinoblastoma. They (31) suggest a mechscreening procedures, since the C-cell hyperplasia, the mananism similar to that proposed for familial polyposis coli and
ifestation of thefirstmutational event, should result at some time
colorectal tumors in which the mutation in the hereditary gene
in elevated calcitonin levels even before the second event has
on chromosome 5 (34) results in hyperplastic cell growth (as do
occurred.
the genes in MEN 2) and subsequent events involving genes at
One clinical implication of this theory is that if it were possiother loci result in further progressive neoplastic changes. In
ble
to prevent the second mutational event from occuning in any
colorectal tumor progression to more malignant stages, an inofthe
predisposed cells, only the hyperplasia would occun It
creasing frequency of genetic alterations has been reported
seems
impossible to maintain known caniers in a mutagen-free
(35-38), especially in 5q, chromosomes 17 and 18, and in the ra.?
environment, although some epidemiologists have suggested a
gene (36). Multiple allelic losses have been found to be dis"Seven Day Adventist life-style" to decrease cancer risks; no
persed throughout the genome in many of the 56 colorectal tualcohol or tobacco exposure, no meat, and many green-yellow
mors studied by the 'Vogelstein group (36-38). An explanation
vegetables daily (41). One factor physicians can control is
proposed (37) was that the heritable mutation included or was
exposure to known mutagenic chemicals as wett as ionizing ralinked to a gene whose product affected neoplastic growth, and
diation from roentgenographic or isotopic studies except when
that inactivation of many different suppressor genes could have
risk-benefit ratios seem very low; perhaps the neck organs and
incremental effects on cell growth. In this theory only one ofthe
adrenals should be protected during roentgenographic studies of
parental alleles would need to be mutated to promote neoplasia,
these patients as is done with the gonads in individuals of childand individual changes would represent single components in a
bearing age. Since MTCs (and other tumors of MEN 2A) are
complex process of tumor evolution. This is similar to the mechgenerally slow-growing and nonaggressive (42), perhaps the
anisms reported by James et al (39) of loss of alleles on one of
greatest benefit of protecting gene carriers from mutagenic exthe two number 10 chromosomes in the progression of glial tuposure can be in limiting occunence of the additional mutagenic
mors. Studies of MEN 2 tumors using markers from many chroevents which are associated with tumor progression. Samaan et
mosomal sites will undoubtedly provide evidence for mutations
al (33) have provided evidence that radiation therapy is associat various loci associated with tumor progression.
ated with decreased survival in MTC patients and that cheIn suggesting possible mechanisms for MEN 2 tumors other
motherapy does not appear to increase survival.
than a homozygous allelic deletion, Nelkin et at (30,31) postuThese hypotheses or views on tumor mechanisms in MEN 2
lated a dominant second event occurring in hyperplastic tissue at
are
subject to testing and possible eventual verification or rejecanother locus on either the same or a different chromosome, or
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tion. tn his conclusion to The Descent of Man, Darwin (43)
stated; " . . . false views, if supported by some evidence, do
little harm, for everyone takes a salutary pleasure in proving
their falseness; and when this is done, one path toward error is
closed and the road to truth is often at the same time opened."
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